Origo Biopharma S.L.
https://origobiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Origo Biopharma S.L.
Taking A Bold Path To Improve Fibrosis Prognosis
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery
Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AgomAb Therapeutics NV
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice